{
  "source": "PA-Notification-Nucala.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1288-9\nProgram Prior Authorization/Notification\nMedications *Nucala® (mepolizumab)\n*This program applies to the prefilled autoinjector and prefilled syringe\nformulations.\nP&T Approval Date 8/2019, 4/2020, 3/2021, 9/2021, 11/2021, 11/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nNucala (mepolizumab) is an interleukin-5 receptor antagonist indicated for add-on maintenance\ntreatment of patients aged 6 years and older with severe asthma and with an eosinophilic phenotype,\nfor add-on maintenance treatment of adult patients 18 years and older with chronic rhinosinusitis with\nnasal polyps (CRSwNP), the treatment of adult patients with eosinophilic granulomatosis with\npolyangiitis (EGPA), and the treatment of adult and pediatric patients aged 12 years and older with\nhypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary\ncause1.\nLimitations of use:\nNucala is not for relief of acute bronchospasm or status asthmaticus.\n2. Coverage Criteriaa:\nA. Eosinophilic granulomatosis with polyangiitis (EGPA)\n1. Initial Authorization\na. Nucala will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Patient has been established on therapy with Nucala under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nEGPA\n-AND-\n(b) Documentation of positive clinical response to Nucala therapy\n-AND-\n(c) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\n© 2024 UnitedHealthcare Services, Inc.\n1\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\n-OR-\n(2) Both of the following:\n(a) Diagnosis of EGPA\n-AND-\n(b) Patient is not receiving Nucala in combination with an",
    "mic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\n-OR-\n(2) Both of the following:\n(a) Diagnosis of EGPA\n-AND-\n(b) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nucala will be approved based on all of the following criterion:\n(1) Documentation of positive clinical response to Nucala therapy\n-AND-\n(2) Patient is not receiving Nucala in combination with any of the following:\n(a) Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\n(d) Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\nB. Asthma\n1. Initial Authorization\na. Nucala will be approved based on one of the following criteria:\n(1) All of the following:\n© 2024 UnitedHealthcare Services, Inc.\n2\n(a) Patient has been established on therapy with Nucala under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nsevere asthma\n-AND-\n(b) Documentation of positive clinical response to Nucala therapy\n-AND-\n(c) Nucala will be used in combination with maintenance controller\nmedications [e.g., combination inhaled corticosteroid (ICS)/long-acting\nbeta2 agonist (LABA), ICS, LABA]\n-AND-\n(d) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin",
    "apy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\n-OR-\n(2) All of the following:\n(a) Diagnosis of severe asthma\n-AND-\n(b) Nucala will be used in combination with maintenance therapy [e.g.,\nAdvair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone\nfuroate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta\n(fluticasone furoate/umeclidinium/vilanterol)].\n-AND-\n(c) Asthma is an eosinophilic phenotype\n-AND-\n(d) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\n© 2024 UnitedHealthcare Services, Inc.\n3\niv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nucala will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Nucala therapy\n-AND-\n(2) Nucala is being used in combination with maintenance therapy [e.g.,\nAdvair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone\nfuroate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta\n(fluticasone furoate/umeclidinium/vilanterol)].\n-AND-\n(3) Patient is not receiving Nucala in combination with any of the following:\n(a) Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\n(d) Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\nC. Hypereosinophilic Syndrome (HES)\n1. Initial Authorization\na. Nucala will be approved bas",
    "opoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\nC. Hypereosinophilic Syndrome (HES)\n1. Initial Authorization\na. Nucala will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Patient has been established on therapy with Nucala under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nHES\n-AND-\n(b) Documentation of positive clinical response to Nucala therapy\n-AND-\n(c) Patient is not receiving Nucala in combination with any of the following:\n© 2024 UnitedHealthcare Services, Inc.\n4\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\n-OR-\n(2) All of the following:\n(a) Diagnosis of HES ≥ 6 months ago\n-AND-\n(b) There is no identifiable non-hematologic secondary cause of the patient’s\nHES (e.g., drug hypersensitivity, parasitic helminth infection, HIV\ninfection, non-hematologic malignancy)\n-AND-\n(c) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nucala will be approved based on both of the following criterion:\n(1) Documentation of positive clinical response to Nucala therapy\n-AND-\n(2) Patient is not receiving Nucala in combination with any of the following:\n(a) Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\n(d) Th",
    "(a) Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\n(d) Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\n© 2024 UnitedHealthcare Services, Inc.\n5\nAuthorization will be issued for 12 months.\nD. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)\n1. Initial Authorization\na. Nucala will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Patient has been established on therapy with Nucala under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nCRSwNP\n-AND-\n(b) Documentation of positive clinical response to Nucala therapy\n-AND-\n(c) Patient will continue to receive Nucala as add-on maintenance therapy\n-AND-\n(d) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\n-OR-\n(2) All of the following:\n(a) Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP).\n-AND-\n(b) Will be used as add-on maintenance therapy\n-AND-\n(c) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\n© 2024 UnitedHealthcare Services, Inc.\n6\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nucala will be approved based on both of the following criterion:\n(1) Documentation of positive clinical response to Nucala therapy\n-AND-\n(2) Patient will continue",
    "for 12 months.\n2. Reauthorization\na. Nucala will be approved based on both of the following criterion:\n(1) Documentation of positive clinical response to Nucala therapy\n-AND-\n(2) Patient will continue to receive Nucala as add-on maintenance therapy\n-AND-\n(3) Patient is not receiving Nucala in combination with any of the following:\n(a) Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\n(d) Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limitations may be in place.\n• Medical Necessity may be in place.\n• The single-dose vial is typically covered under the medical benefit. Please refer to the United\nHealthcare Medical Benefit Drug Policy: “Respiratory Interleukins (Cinqair®, Fasenra®, and\nNucala®)”.\n4. References:\n1. Nucala® [package insert]. Research Triangle Park, NC; GlaxoSmithKline, LLC; March 2023.\n© 2024 UnitedHealthcare Services, Inc.\n7\nProgram Prior Authorization/Notification - Nucala (mepolizumab)\nChange Control\n8/2019 New program.\n4/2020 Updated program to address specific product formulations. Updated\nreferences.\n3/2021 Updated program to add HES indication and update age requirement for\nsevere asthma indication. Added limitations of use. Updated references.\n9/2021 Added coverage criteria for new indication, chronic ",
    "Updated program to add HES indication and update age requirement for\nsevere asthma indication. Added limitations of use. Updated references.\n9/2021 Added coverage criteria for new indication, chronic rhinosinusitis with\nnasal polyps. Updated background and references.\n11/2021 Added coverage criteria for patients established on therapy under\nUnitedHealthcare medical benefit.\n1/2022 Administrative change to fix typo.\n11/2022 Annual review. Updated criteria for patients established on Nucala\nunder active UHC PA for Asthma and CRSwNP. Added state mandate\nfootnote and updated reference.\n7/2023 Within the Asthma section, added/updated examples of ICS-containing\nmaintenance medications, removed bypass of eosinophilic phenotype\nrequirement for patients currently dependent on maintenance therapy\nwith oral corticosteroid, and added Tezspire to list of agents that should\nnot be used in combination with Nucala.\n7/2024 Annual review. Updated background with modified indication for\nCRSwNP. Removed nasal corticosteroid requirement in CRSwNP\ncriteria. Added Tezspire to list of drugs not allowed for concomitant\nuse. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n8"
  ]
}